- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 239/22 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
Patent holdings for IPC class C07D 239/22
Total number of patents in this class: 272
10-year publication summary
|
19
|
8
|
29
|
19
|
21
|
16
|
17
|
12
|
11
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Cv6 Therapeutics (NI) Limited | 31 |
16 |
| PH Pharma Co., Ltd. | 29 |
8 |
| The Walter and Eliza Hall Institute of Medical Research | 168 |
8 |
| BASF SE | 20367 |
7 |
| Japan Tobacco Inc. | 3481 |
7 |
| Merck Sharp & Dohme LLC | 3742 |
7 |
| Merck Sharp & Dohme Corp. | 2218 |
6 |
| F. Hoffmann-La Roche AG | 7942 |
5 |
| Janssen Pharmaceutica N.V. | 3625 |
5 |
| Autifony Therapeutics Limited | 47 |
5 |
| MSD R & D (China) Co. LTD. | 53 |
5 |
| VALO Health, Inc. | 167 |
5 |
| Centre National de La Recherche Scientifique | 10052 |
4 |
| Cellix Bio Private Limited | 51 |
4 |
| Sunshine Lake Pharma Co., Ltd. | 567 |
4 |
| UCB Biopharma SRL | 644 |
4 |
| Shanghai Leadingtac Pharmaceutical Co., Ltd. | 18 |
4 |
| Glaxosmithkline LLC | 541 |
3 |
| Abbott Laboratories | 2464 |
3 |
| Wisconsin Alumni Research Foundation | 3819 |
3 |
| Other owners | 159 |